Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

KE108

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Medullary thyroid cancer (MTC) is often resistant to standard therapies, emphasizing the need for the development of other… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2017
Highly Cited
2017
Although neuroendocrine tumors (NETs) are slow growing, they are frequently metastatic at the time of discovery and no longer… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Neuroendocrine (NE) cancers can cause significant patient morbidity. Besides surgery, there are no curative treatments for NE… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
Review
2013
Review
2013
Introduction: Neuroendocrine and pituitary tumors are uncommon tumors that develop from cells of the (neuro-)endocrine system… 
2011
2011
The somatostatin receptor subtype 2A (sst2A) mediates many of somatostatin's neuroendocrine actions and is the primary… 
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
Somatostatin analogs that activate the somatostatin subtype 2A (sst2A) receptor are used to treat neuroendocrine cancers because… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Highly Cited
2006
Highly Cited
2006
UNLABELLED The uptake of radiolabeled somatostatin analogs by tumor cells through receptor-mediated internalization is a critical… 
Highly Cited
2005
Highly Cited
2005
Upon hormone stimulation, the sst2 somatostatin receptor couples to adenylyl cyclase through Gi/o proteins and undergoes rapid… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4